Journal
NATURE NEUROSCIENCE
Volume 5, Issue -, Pages 1039-1042Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nn936
Keywords
-
Categories
Ask authors/readers for more resources
Since the mid 1980s, there has been a great deal of enthusiasm within both academia and industry about the therapeutic potential of drugs targeting the NMDA subtype of glutamate receptors. That early promise is just beginning to translate into approvable drugs. Here we review the reasons for this slow progress and critically assess the future prospects for drugs that act on NMDA receptor pathways, including potential treatments for some major disorders such as stroke and Alzheimer's disease, for which effective therapies are still lacking.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available